Quick Facts
Plain-English Summary
5-Amino-1MQ is a synthetic small molecule designed to inhibit Nicotinamide N-methyltransferase (NNMT), an enzyme that becomes strongly upregulated in adipose tissue in the context of obesity and metabolic dysfunction. NNMT consumes S-adenosyl methionine (SAM) — the body's primary methyl donor — and in doing so depletes a key substrate required for NAD+ biosynthesis and broader cellular methylation. The core hypothesis is that by blocking NNMT, researchers can preserve SAM and restore downstream metabolic pathways that are suppressed in obese or insulin-resistant states.
The primary preclinical findings come from high-fat diet (HFD) mouse models. In those studies, NNMT inhibition — achieved through small molecule inhibitors including compounds structurally related to 5-Amino-1MQ — reduced fat cell size, increased energy expenditure, and in a notable 2018 study by Kannt et al., prevented the development of obesity in mice fed a high-fat diet, without caloric restriction. A complementary body of work from Neelakantan and colleagues examined the structural and mechanistic basis for quinolinium-based NNMT inhibitors, providing some pharmacological rationale for this class of compound.
The connection to the NAD+ pathway has attracted significant biohacker interest, as NAD+ augmentation is a parallel area of active research. However, 5-Amino-1MQ's mechanism is upstream — it preserves the substrates that feed into NAD+ synthesis — and the two are not interchangeable. Extrapolating the NAD+ evidence base to 5-Amino-1MQ is not scientifically supported.
As of 2026, 5-Amino-1MQ has no published human pharmacokinetic data, no dose-ranging studies in humans, and no registered or completed human clinical trials for any indication. It is among the most early-stage compounds in this entire catalogue. The entire evidence base is preclinical — cell culture and mouse models only.
Community interest is driven primarily by the theoretical appeal of targeting a metabolically relevant enzyme without caloric restriction, and by anecdotal reports in biohacking forums. The gap between these reports and the available scientific evidence is very large. Researchers and clinicians uniformly note that preclinical metabolic findings in rodents have a poor translational record in humans, and that NNMT's role in human adipose biology, while studied, has not established a clear therapeutic target at this dose or via this compound class.
Mechanism of Action
Proposed mechanisms below are derived from in vitro and rodent studies only. No mechanistic pathway has been validated in a controlled human study.
All mechanistic data is derived from in vitro or rodent studies. Applicability of these pathways in humans is not established.
Animal Data
| Model | Finding | ICPS Status |
|---|---|---|
| HFD mice — obesity prevention (Kannt et al.) | NNMT inhibition prevented development of diet-induced obesity in mice fed a high-fat diet, without caloric restriction. Reduced adipose mass and improved metabolic markers vs. untreated controls. Kannt A et al. 2018 ↗ | Preclinical |
| Adipose tissue cell culture | Quinolinium-based NNMT inhibitors (structurally related to 5-Amino-1MQ) reduced lipid accumulation in differentiating adipocytes in vitro. SAM levels increased and NNMT activity was dose-dependently suppressed. Neelakantan H et al. 2017 ↗ | Preclinical |
| Obese mouse adipose — fat cell size | Reduction in fat cell (adipocyte) diameter and increased expression of thermogenic markers in white adipose tissue following NNMT inhibitor treatment. Results suggest a metabolic shift rather than simple lipolysis. | Preclinical |
| Metabolic syndrome markers (rodent) | Improvements in insulin sensitivity and fasting glucose observed in some rodent studies co-reporting NNMT inhibition. Effect sizes were modest and context-dependent. Independent replication is limited. | Preclinical |
No finding from this section has been replicated in a controlled human trial. Animal-to-human translation for peptides is uncertain and cannot be assumed.
Human Trials
| Trial | Population | Status | ICPS Status |
|---|---|---|---|
| All indications | — | — | No Data |
5-Amino-1MQ has no FDA, EMA, or Health Canada–approved indications and no published Phase III trial data for any condition as of 2026.
Safety & Side Effects
Formal toxicology data for 5-Amino-1MQ specifically is not publicly available. Some related NNMT inhibitor compounds were evaluated in rodent models without acute toxicity signals at research doses, but no comprehensive safety profiling for this compound has been published.
NNMT plays roles beyond adipose metabolism, including in cancer biology, liver function, and immune regulation. Systemic NNMT inhibition could have unintended effects on these systems. The long-term consequences of NNMT inhibition in humans are entirely unknown.
- Injection site irritation (primary route used in community)
- Gastrointestinal discomfort reported anecdotally
- Fatigue and headache in early days of use
- No pharmacovigilance database exists for 5-Amino-1MQ
- Self-reports are unverified and subject to significant bias
- Active or suspected malignancy (NNMT is implicated in cancer biology)
- Liver disease or hepatic dysfunction
- Pregnancy or breastfeeding
- Immunosuppressive therapy
- Children and adolescents
- Any use without institutional research oversight
5-Amino-1MQ is not approved by the FDA, EMA, or Health Canada for any medical indication. It is classified as a research compound and is not legal for human therapeutic use in most jurisdictions. Procurement and use outside of registered clinical trials carries regulatory and unknown health risks.
References
Research disclaimer. CompoundProfile publishes summaries of available scientific literature for educational purposes only. This page does not constitute medical advice and should not be interpreted as an endorsement of 5-Amino-1MQ for any therapeutic use. Consult a licensed healthcare professional before considering any research compound. All evidence gradings reflect the state of published literature as of August 2026 and are assessed independently by ICPS.
Community Commentary
Selected discussion from r/Peptides · Curated for signal, not volume
The NNMT inhibition story is mechanistically interesting — the SAM depletion angle in obese adipose tissue is real and the Kannt 2018 paper is credible work. The problem is that "mechanistically interesting in mouse fat cells" and "works in humans" are separated by a very wide gap that nobody has crossed yet. What I see circulating in the community is the conclusion without the middle part. Fat loss in HFD mice without caloric restriction sounds compelling, but the translational graveyard is full of compounds that did exactly this.
Agreed, and I'd add that the NAD+ framing is being borrowed from a completely different evidence base. People are combining the NR/NMN literature — which does have some human data — with 5-Amino-1MQ's upstream mechanism and presenting it as though the evidence transfers. It doesn't. NNMT inhibition is upstream of NAD+ salvage, yes, but that's a theoretical connection, not a proven one in humans.
One thing worth flagging: NNMT is not uniquely expressed in fat tissue. It's upregulated in several cancer types and plays a role in the tumour microenvironment. There's a meaningful body of oncology literature on NNMT as a tumour-promoting factor. That doesn't mean 5-Amino-1MQ causes cancer — the causality isn't established — but it does mean that systemic NNMT inhibition could have off-target effects in tissues where NNMT serves a different function. Nobody discussing this compound in biohacking forums seems to be aware of the cancer biology angle at all.
I track the PK question for a lot of compounds and 5-Amino-1MQ is notable for having essentially zero published data on what happens after subcutaneous injection in any mammal. We don't know half-life, we don't know volume of distribution, we don't know if it even reaches adipose tissue at meaningful concentrations after SC dosing in humans. The mouse studies used specific injection protocols that aren't equivalent to what people are doing at home. The dosing protocols circulating in forums are genuinely made up — there's no published basis for any of them.
This is the core problem. It's not that the compound is obviously harmful — it might turn out to be interesting — it's that we're at the "promising rodent finding" stage of the research pipeline and the community has jumped to the end. That gap is exactly where most compounds fail. Keep it on the watchlist, wait for human PK data, and be very cautious about anything from vendors claiming clinical evidence.
To be clear about what "evidence" means here: we have a handful of mouse papers showing that blocking NNMT has metabolic effects in obese rodents, and some in vitro work on the quinolinium inhibitor class. That's a legitimate and interesting starting point for a drug development program. It is not evidence that injecting this compound into yourself will produce weight loss or any other effect. Those are completely different claims. The enthusiasm in the community is understandable but it's getting ahead of the science by at least a decade.